Abstract
To compare the effect of oral glucocorticoid (GC) therapy with the effect of intravenous anti-TNF-α-therapy on serum VEGF levels of patients with rheumatoid arthritis (RA). Five RA patients (5/8) who had no prior treatment with DMARDs (Disease modifying antirheumatic drugs) or GCs were administered 20 mg prednisolone daily. Three patients who failed more than one DMARD therapy received infusion with Infliximab (200 mg). VEGF-serum levels were measured by enzyme-linked immunosorbent assay before treatment,and at day 10 or 13 during prednisolone therapy, or 14 days after the first Infliximab infusion. Serum VEGF levels in therapy naive RA patients (GC group) were higher than those in pretreated patients who received Infliximab (median serum VEGF level: 1106 vs 320 pg/ml; P=0.1). Treatment with Infliximab as well as GCs significantly decreased serum VEGF levels after 10–14 days in RA patients (median serum VEGF level after treatment: GC group 559 pg/ml, Infliximab group 92 pg/ml; P=0.01 vs without treatment or preinfusion). Conclusions: Anti-TNF-α antibody Infliximab as well as GC are able to decrease serum VEGF levels in patients with active RA. Whether therapeutic reduction of serum VEGF levels is associated with inhibition of angiogenesis should be evaluated in future by imaging of synovial vasculature.
Similar content being viewed by others
References
Schrieber L, Jackson JC (2004) Angiogenesis in Rheumatoid Arthritis. In: Klippel HJ, Dieppe PA (eds) Rheumatology, 2nd edn, vol 1. Mosby International, London, England, pp 12.1–12.4
Koch AE (1998) Angiogenesis—implications for rheumatoid arthritis. Arthritis Rheum 41(6):951–962
Jain A, Nanchahal J, Troeberg L, Green P, Brennan F (2001) Production of cytokines, vascular endothelial growth factor, matrix metalloproteinases, and tissue inhibitor of metalloproteinases 1 by tenosynovium demonstrates its potential for tendon destruction in rheumatoid arthritis. Arthritis Rheum 44(8):1754–1760
Koch AE, Volin MV, Woods JM, Kunkel SL, Connors MA, Harlow LA, Woodruff DC, Burdick MD, Strieter RM (2001) Regulation of angiogenesis by the C-X-C chemokines interleukin-8 and epithelial neutrophil activating peptide 78 in the rheumatoid joint. Arthritis Rheum 44(1):31–40
Paleolog EM (1996) Angiogenesis: a critical process in the pathogenesis of RA—a role of VEGF?. Br J Rheumatol 35:917–919
Afuwape AO, Kiriakidis S, Paleolog EM (2002) The role of the angiogenic molecule VEGF in the pathogenesis of rheumatoid arthritis. Histol Histopathol 17(3):961–972
Nagashima M, Yoshino S, Ishiwata T, Asano G (1995) Role of vascular endothelial growth factor in angiogenesis of rheumatoid arthritis. J Rheumatol 22:1624–1630
Kasama T, Shiozawa F, Kobayashi K, Yajima N, Hanyuda M, Takeuchi HT, Mori Y, Negishi M, Ide H, Adachi M (2001) Vascular endothelial growth factor expression by activated synovial leukocytes in rheumatoid arthritis. Arthritis Rheum 44(11):2512–2524
Harada M, Mitsuyama K, Yoshida H, Sakisaka S, Taniguchi E, Kawaguchi T, Ariyoshi M, Saiki T, Sakamoto M, Nagata K, Sata M, Matsuo K, Tanikawa K (1998) Vascular endothelial growth factor in patients with rheumatoid arthritis. Scand J Rheumatol 27:377–380
Wauke K, Nagashima M, Ishiwata T, Asano G, Yoshino S (2002) Expression and localization of vascular endothelial growth factor-C in rheumatoid arthritis synovial tissue. J Rheumatol 29(1):34–38
Latour F, Zabraniecki L, Dromer C, Brouchet A, Durroux R, Fournie B (2001) Does vascular endothelial growth factor in the rheumatoid synovium predict joint destruction? A clinical, radiological and pathological study in 12 patients monitored for 10 years. Joint Bone Spine 68(6):493–498
Ballara S, Taylor PC, Reusch P, Marme D, Feldmann M, Maini RN, Paleolog EM (2001) Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum 44(9):2055–2064
Paleolog EM, Young S, Stark AC, McCloskey RV, Feldmann M, Maini R (1998) Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor α and interleukin-1 in rheumatoid arthritis. Arthritis Rheum 41(7):1258–1265
Nakahara H, Song J, Sugimoto M, Hagihara K, Kishimoto T, Yoshizaki K, Nishimoto N (2003) Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum 48(6):1521–1529
Ha IS, Um EY, Jung HR, Park HW, Cheong HI, Choi Y (2002) Glucocorticoid diminishes vascular endothelial growth factor and exacerbates proteinuria in rats with mesangial proliferative glomerulonephritis. Am J Kidney Dis 39(5):1001–1010
Pinheiro GR, Andrade CA, Gayer CR, Coelho MS, Freire SM, Scheinberg MA (2001) Serum vascular endothelial growth factor in late rheumatoid arthritis. Clin Exp Rheumatol 19(6):721–723
Kompella UB, Bandi N, Ayalasomayajula SP (2003) Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression. Invest Ophtalmol Vis Sci 44(3):1192–1201
Edelman JL, Castro MR, Wen Y (1999) Correlation of VEGF expression by leukocytes with the growth and regression of blood vessels in the rat cornea. Invest Ophtalmol Vis Sci 40(6):1112–1123
Nauck M, Karakiulakis G, Perruchoud AP, Papakonstantinou E, Roth M (1998) Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol 341(2–3):309–315
Bandi N, Kompella UB (2001) Budesonide reduces vascular endothelial growth factor secretion and expression in airway (Calu-1) and alveolar (A549) epithelial cells. Eur J Pharmacol 425(2):109–116
Meliconi R, Pulsatelli L, Dolzani P, Boiardi L, Macchioni P, Salvarani C, Silvestri T, Frizziero L (2000) Vascular endothelial growth factor production in polymyalgia rheumatica. Arthritis Rheum 43(11):2472–2480
Nagashima M, Wauke K, Hirano D, Ishigami S, Aono H, Takai M, Sasano M, Yoshino S (2000) Effects of combinations of anti-rheumatic drugs on the production of vascular endothelial growth factor and basic fibroblast growth factor in cultured synoviocytes and patients with rheumatoid arthritis. Rheumatology 39:1255–1262
Lee SS, Joo YS, Kim WU, Min DJ, Min JK, Park SH, Cho CS, Kim HY (2001) Vascular endothelial growth factor levels in the serum and synovial fluid of patients with rheumatoid arthritis. Clin Exp Rheumatol 19(3):321–324
Strunk J, Lange U, Kürten B, Schmidt KL, Neeck G (2003) Doppler sonographic findings in the long bicipital tendon sheath in patients with rheumatoid arthritis as compared with patients with degenerative diseases of the shoulder. Arthritis Rheum 48(7):1828–1832
Terslev L, Torp-Pedersen S, Savnik A, von der Recke P, Qvistgaard E, Danneskiold-Samsoe B, Bliddal H (2003) Doppler ultrasound and magnetic resonance imaging of synovial inflammation of the hand in rheumatoid arthritis: a comparative study. Arthritis Rheum 48(9):243–241
Strunk J, Lange U (2004) Three-dimensional power Doppler sonographic visualization of synovial angiogenesis in rheumatoid arthritis. J Rheumatol 31(5):1004–1006
Strunk J, Heinemann E, Schmidt KL, Neeck G, Lange U (2004) A new approach to studying angiogenesis in rheumatoid arthritis by means of power Doppler ultrasonography and serum vascular endothelial growth factor (VEGF) level measurement. Rheumatology 43:1480–1483
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Strunk, J., Bundke, E. & Lange, U. Anti-TNF-α antibody Infliximab and glucocorticoids reduce serum vascular endothelial growth factor levels in patients with rheumatoid arthritis: a pilot study. Rheumatol Int 26, 252–256 (2006). https://doi.org/10.1007/s00296-005-0619-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-005-0619-5